Differential Activation of Neuroinflammatory Pathways in Children with Seizures: A Cross-Sectional Study

Approximately 50 million people worldwide are affected by epilepsy [1]. Approximately one-third of them are considered pharmaco-resistant [2] and experience seizures despite complex therapeutic regimens, often burdened by significant side-effects. Current antiseizure medications (ASM) target seizures symptomatically but not underlying pathophysiological mechanisms [3]. Experimental and clinical findings suggest a crucial role of inflammation in epileptogenesis [4]. New therapeutic strategies are necessary to improve seizure control and quality of life for people with epilepsy.

Source: Seizure: European Journal of Epilepsy - May 30, 2021 Category: Neurology Authors: Luca Bartolini, Michael P. Moran, Gina Norato, Bobbe Thomas, Alexander D. Dick, Elizabeth Wells, William Suslovic, Adrian Bumbut, James M. Chamberlain, William H. Theodore, William D. Gaillard, Steven Jacobson Source Type: research